Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6A1A2
UPID:
PDPK2_HUMAN
Alternative names:
3-phosphoinositide-dependent protein kinase 2 pseudogene
Alternative UPACC:
Q6A1A2
Background:
The Putative 3-phosphoinositide-dependent protein kinase 2, alternatively known as 3-phosphoinositide-dependent protein kinase 2 pseudogene, plays a pivotal role in cellular signaling pathways. It is known for its ability to phosphorylate and activate a variety of kinases including PKB/AKT, PKA, PKC-zeta, RPS6KA1, and RPS6KB1. This broad spectrum of activity suggests its involvement in crucial signaling processes and developmental functions, highlighting its significance in cellular biology.
Therapeutic significance:
Understanding the role of Putative 3-phosphoinositide-dependent protein kinase 2 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways makes it a promising target for drug discovery, aiming to modulate its activity for therapeutic benefits.